Results 311 to 320 of about 196,164 (338)

Rituximab

Reactions Weekly, 2017
  +4 more sources

Rituximab versus tocilizumab in anti-TNF inadequate responder patients with rheumatoid arthritis (R4RA): 16-week outcomes of a stratified, biopsy-driven, multicentre, open-label, phase 4 randomised controlled trial

Lancet, The, 2021
Frances Humby, Patrick Durez, Maya H Buch   +2 more
exaly  

Rituximab

Reactions Weekly, 2012
openaire   +2 more sources

Anti-CD47 Antibody Synergizes with Rituximab to Promote Phagocytosis and Eradicate Non-Hodgkin Lymphoma

Cell, 2010
Ash A Alizadeh, June Helen Myklebust, Raquel Malumbres   +2 more
exaly  

Rituximab

Reactions Weekly, 2015
openaire   +2 more sources

Addition of rituximab to fludarabine and cyclophosphamide in patients with chronic lymphocytic leukaemia: a randomised, open-label, phase 3 trial

Lancet, The, 2010
Pier Luigi Zinzani
exaly  

Safety and efficacy of rituximab in neuromyelitis optica spectrum disorders (RIN-1 study): a multicentre, randomised, double-blind, placebo-controlled trial

Lancet Neurology, The, 2020
Masayuki Tahara, Kazuhide Ochi, Hirofumi Maruyama   +2 more
exaly  

Rituximab for rheumatoid arthritis refractory to anti-tumor necrosis factor therapy: Results of a multicenter, randomized, double-blind, placebo-controlled, phase III trial evaluating primary efficacy and safety at twenty-four weeks.

Arthritis & Rheumatism, 2006
S. Cohen, P. Emery, M. Greenwald, M. Dougados, R. Furie, M. Genovese, E. Keystone, J. Loveless, G. Burmester, M. Cravets, E. Hessey, T. Shaw, M. Totoritis   +12 more
semanticscholar   +1 more source

Rituximab maintenance for 2 years in patients with high tumour burden follicular lymphoma responding to rituximab plus chemotherapy (PRIMA): a phase 3, randomised controlled trial

Lancet, The, 2011
Fritz Offner, Armando López-Guillermo, David Belada   +2 more
exaly  

CHOP-like chemotherapy plus rituximab versus CHOP-like chemotherapy alone in young patients with good-prognosis diffuse large-B-cell lymphoma: a randomised controlled trial by the MabThera International Trial (MInT) Group

Lancet Oncology, The, 2006
Michael Pfreundschuh, Marek Trneny, Jan A Walewski   +2 more
exaly